That mechanism is the entire point, and it works: roughly 18% of US adults have tried a GLP-1 and about 12% are currently taking one (KFF Health Tracking Poll), according to KFF survey data
Selank Selank is a synthetic heptapeptide based on the immunomodulatory molecule tuftsin and approved in Russia for the treatment of anxiety
In a phase I trial of community-dwelling adults with mild to moderate AD, daily supplementation with a 6-ingredient nutraceutical formulation (NF) including 800 mg of SAMe resulted in statistically significant improvements in both cognitive function and severity of behavioural and psychiatric symptoms of dementia (BPSD) within 6 months, with improvement maintained for 28 months (52)
To explore whether it is right for you, ask our team about our broader peptide therapy program at your consultation
launched July 1, 2026 through December 31, 2027 Who Faces the Greatest Need for This Coverage The groups most likely to benefit from the Medicare GLP-1 Bridge program include: Medicare Part D enrollees ages 65 and older with a body mass index of 35 or higher, or a BMI of 27 or higher combined with a qualifying condition such as cardiovascular disease or prediabetes Adults with obesity who were previously unable to afford brand-name GLP-1 medications on fixed retirement incomes People who discontinued brand-name GLP-1 treatment due to cost and are eligible to re-enter with the $50 Bridge copay Patients managing obesity-related conditions including hypertension, sleep apnea, and prediabetes, who may reduce downstream healthcare costs through weight management People who already receive GLP-1 coverage through their Part D plan for diabetes, cardiovascular disease, or sleep apnea do not qualify for the Bridge program they continue to access the drugs through their existing coverage
And it's like a better digestive experience when you have all of those different senses playing a part
